Generic Name: ziv-aflibercept

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Sanofi/Genzyme

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Zaltrap is a VEGF inhibitor approved for treatment of metastatic colorectal cancer that progresses after chemotherapy.

General Info

Zaltrap binds to vascular endothelial growth factor (VEGF), which is important for the development of blood vessels that feed tumors.

Clinical trials showed that Zaltrap delays disease progression and improves survival in people with metastatic colorectal cancer that worsened after chemotherapy. It was first approved in 2012.


Dosing Info:

Zaltrap is given by intravenous infusion. It should be used in combination with a chemotherapy regimen known as FOLFIRI.

Side Effects

Common side effects include diarrhea, high blood pressure, mouth sores, decreased appetite, weight loss, headache and elevated liver enzymes. Zaltrap can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential serious side effects may include blood clots in arteries, severe hypertension, protein loss in the urine and fistula formation. The Zaltrap label includes a warning about the risk of severe bleeding (hemorrhage), gastrointestinal perforation and slow wound healing.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 16, 2018